Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
1.000
+0.030 (3.09%)
Dec 26, 2024, 3:54 PM EST - Market open
Oncolytics Biotech Employees
Oncolytics Biotech had 29 employees as of December 31, 2022. The number of employees increased by 3 or 11.54% compared to the previous year.
Employees
29
Change (1Y)
3
Growth (1Y)
11.54%
Revenue / Employee
n/a
Profits / Employee
-$705,557
Market Cap
75.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| bluebird bio | 375 |
| InterCure | 270 |
| Atara Biotherapeutics | 225 |
| Adicet Bio | 143 |
| InspireMD | 66 |
| PMV Pharmaceuticals | 63 |
| Aerovate Therapeutics | 51 |
| Quince Therapeutics | 32 |
ONCY News
- 3 days ago - Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data - PRNewsWire
- 8 days ago - Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium - PRNewsWire
- 23 days ago - Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort - PRNewsWire
- 6 weeks ago - Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights - PRNewsWire
- 6 weeks ago - Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - PRNewsWire
- 2 months ago - Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path - PRNewsWire
- 3 months ago - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study - PRNewsWire